Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.39 |
| ▸ | LIPE | Q05469 | 2/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24792914 | 0.83 | CREBBP (0.41) | LIPEGPR119 | |
| SCHEMBL29709817 | 0.83 | CREBBP (0.41) | LIPEGPR119 | |
| SCHEMBL24794687 | 0.82 | TP53 (0.42) | LIPEUSP30 | |
| SCHEMBL24792917 | 0.82 | NR1H2 (0.47) | EPHX2ENPP2KMT2A | |
| SCHEMBL24794177 | 0.77 | ALDH1A1 (0.50) | GPR119 | |
| SCHEMBL24793521 | 0.77 | HDAC1 (0.42) | LIPEUSP30PDE4BGPR119 | |
| SCHEMBL24793552 | 0.77 | PDE4B (0.50) | EPHX2ENPP2USP30PDE4B | |
| SCHEMBL24794727 | 0.76 | CREBBP (0.40) | EPHX2ENPP2 | |
| SCHEMBL29709668 | 0.76 | CREBBP (0.40) | EPHX2ENPP2 | |
| SCHEMBL24792916 | 0.74 | HTR2A (0.45) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402901-A1 | SUBSTITUTED N-HETEROCYCLIC CARBOXAMIDES AS ACID CERAMIDASE INHIBITORS AND THEIR USE AS MEDICAMENTS | BIAL R&D INVEST S A (PT) | 2022-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402901-A1 | SUBSTITUTED N-HETEROCYCLIC CARBOXAMIDES AS ACID CERAMIDASE INHIBITORS AND THEIR USE AS MEDICAMENTS | ASAH2, ASAH1, GBA1 | EPHX2 607/4885ENPP2 48/4885LIPE 403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.